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ABSTRACT The ErbB2 oncogene is often overex-
pressed in breast tumors and associated with poor clinical
outcome. p130Cas represents a nodal scaffold protein
regulating cell survival, migration, and proliferation in
normal and pathological cells. The functional role of
p130Cas in ErbB2-dependent breast tumorigenesis was
assessed by its silencing in breast cancer cells derived
from mouse mammary tumors overexpressing ErbB2
(N202-1A cells), and by its reexpression in ErbB2-trans-
formed p130Cas-null mouse embryonic fibroblasts. We
demonstrate that p130Cas is necessary for ErbB2-depen-
dent foci formation, anchorage-independent growth, and
in vivo growth of orthotopic N202-1A tumors. Moreover,
intranipple injection of p130Cas-stabilized siRNAs in the
mammary gland of Balbc-NeuT mice decreases the
growth of spontaneous tumors. In ErbB2-transformed
cells, p130Cas is a crucial component of a functional
molecular complex consisting of ErbB2, c-Src, and Fak. In
human mammary cells, MCF10A.B2, the concomitant
activation of ErbB2, and p130Cas overexpression sustain
and strengthen signaling, leading to Rac1 activation and
MMP9 secretion, thus providing invasive properties. Con-
sistently, p130Cas drives N202-1A cell in vivo lung
metastases colonization. These results demonstrate that
p130Cas is an essential transducer in ErbB2 transforma-
tion and highlight its potential use as a novel therapeutic
target in ErbB2 positive human breast cancers.—Cabodi,
S., Tinnirello, A., Bisaro, B., Tornillo, G., Camacho-Leal,
M. P., Forni, G., Cojoca, R., Iezzi, M., Amici, A., Montani,
M., Eva, A., Di Stefano, P., Muthuswamy, S. K., Tarone,
G., Turco, E., Defilippi, P. p130Cas is an essential trans-
ducer element in ErbB2 transformation. FASEB J. 24,
000–000 (2010). www.fasebj.org
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The ErbB2 oncogene (also known as HER2) belongs
to the epidermal growth factor-receptor family, and its
overexpression and activation have been detected in a
large subset of mammary cancers (1, 2). Molecular and
clinical studies indicate that ErbB2 has important im-
plications in tumor etiology and progression. Activated
ErbB2 stimulates many intracellular signaling mole-
cules, including the mitogen-activated protein kinase,
Src kinase, and phospholipase C gamma (3).
p130Cas was originally identified as a tyrosine phos-
phorylated protein on transformation by v-Src and
v-Crk oncogenes and for its ability to associate with Crk
(4, 5). p130Cas structural motifs and its post-transla-
tional modifications enable mechanical extension (6)
and interactions with many proteins leading to multi-
protein complexes (7–9). In normal cells, p130Cas
modulates cell motility, survival, and proliferation (10).
In particular, c-Src-mediated p130Cas phosphorylation
and the assembly of a p130Cas–Crk–DOCK180 scaffold
drive cell migration and responses to mechanical stress
(11–13).
p130Cas is emerging as an important player in the
transformation and invasion driven by different onco-
genes. Its involvement in c-Src-mediated tumorigenesis
has been demonstrated by the inability of c-Src to
transform p130Cas-null MEFs (14). It has also been
reported recently that knockdown of p130Cas causes
proliferative arrest in breast cancer cell lines harboring
oncogenic mutations in KRAS, BRAF, PTEN, and
PIK3CA (15), underlying a role for p130Cas as a
general regulator of breast cancer cell growth induced
by different oncogenes.
We have previously shown that double-transgenic mice
originated by crossing MMTV-p130Cas and MMTV-NeuT
mice, which express the oncogenic form of the rat neu gene,
homologous to human ErbB2 (16, 17), showed an acceler-
ated onset of mammary tumor formation (10). In addition,
the analysis of human breast samples revealed that tumors
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overexpressing both p130Cas and ErbB2 are characterized
by an elevated proliferation index (10).
In this work, the role of p130Cas in ErbB2 transfor-
mation was assessed in epithelial cells expressing the
ErbB2 proto-oncogene and closely mimicking the hu-
man pathology (N202-1A and 10A.B2). As an alterna-
tive genetically relevant model for molecular and func-
tional studies in a p130Cas null background, mouse
embryo fibroblasts (MEFs) derived from knockout an-
imals were also used (14). Moreover, human 10A.B2
mammary epithelial cells expressing a synthetic-ligand-
inducible ErbB2 receptor (20) were used in 2- and
3-dimensional (2-D and 3-D) cultures. In these cells,
ErbB2 activation interferes with the physiological mor-
phogenetic process of mammary acini formation and
reinitiates proliferation, disrupting cell polarity and
giving rise to multiacinar, noninvasive structures, mim-
icking the early stages of breast cancer. By these means,
we demonstrate that p130Cas is necessary for ErbB2
transformation, and is required to trigger growth and
invasion of ErbB2-transformed cancer cells.
MATERIALS AND METHODS
Antibody, reagents, inhibitors, and mice
p130Cas mAbs have been previously described (10). mAbs
CB11 to ErbB2 was from Novocastra Laboratories (New-
castle, UK). An additional mAb directed to the cytoplasmic
domain of ErbB2 was prepared in our laboratory, by
immunizing mice with a recombinant protein encompass-
ing amino acids 1031–1160 of rat ErbB2 cDNA sequence.
mAbs to Fak, GFP, Rac 1, lamininV, and vinculin were from
Millipore (Billerica, MA, USA). Antibodies to c-Src, p-Tyr
PY99, and actin were from Santa Cruz Biotechnologies
(Palo Alto, CA, USA). Cleaved caspase 3, pTyr925 Fak,
p314Fak, and pTyr416 Src antibodies were from Cell
Signaling (Beverly, MA, USA). KI67 mAbs were from
Novocastra Laboratories. Matrigel and collagen I were
from BD Transduction Laboratories (Franklin Lakes, NJ,
USA). Secondary antibodies conjugated with peroxidase
were from Sigma (St. Louis, MO, USA). Secondary anti-
bodies conjugated with FITC and TRITC were from Alexa
Molecular Probes (Invitrogen, Carlsbad, CA, USA).
SU6656 was from Calbiochem (San Diego, CA, USA), PT
573228 was obtained from Tocris (Ellisville, MO, USA) and
Lapatinib was a kind gift of Dr. Giorgio Vállabrega (Istituto
per la Ricerca e Cura del Cancro, Candiolo, Italy). Mice
were from Charles River Laboratories (Calco, Italy).
Cell cultures
NIH3T3 were maintained in DMEM, 10% CS. MEFs were
cultured in DMEM, 10% FCS, and N202-1A cells in DMEM-
20% FCS. 10A.B2 cell cultures and 3-D assays were per-
formed in agreement with protocols reported online
(http://muthuswamylab.cshl.edu/ml_protocols/html).
Live images were collected by using Zeiss microscopy (Carl
Zeiss, Oberkochen, Germany) at 20 or 63.
Generation of recombinant retroviruses and inducible
lentiviruses
FL BamHI/SalI p130Cas cDNA from pcDNA3 (10) was
cloned into pBabe-GFP. pBabe-ErbB2(VE) retrovirus was
described by Holbro et al. (18). MEFs or 10A.B2 cells were
infected with viral particles from 293-GP packaging cells
and selected with 1 g/ml puromycin and 200 g/ml
HygromycinB (Sigma).
p130Cas-shRNA (5GGAGGTGTCTCGTCCAATA3) and
scramble-shRNA (Ctr) (5GCCCAGCCACGGACCTTTA3)
sequences were obtained by Sigma and cloned into pSuper
Retro. Subcloning into pLVTHM lentiviral vectors, viral pro-
duction, and N202-1A cell infection was described by Trono
(19). For p130Cas reconstitution, human p130Cas cDNA was
cloned into pCCL lentiviral vector, and viral particles produc-
tion was performed as described above.
Immunoblotting, immunoprecipitation analysis, Rac1
pulldown assay, and gelatin zymography
Protein extracts, WB, and IPs were performed as described by
Cabodi et al. (20). Rac1 pulldown assay was performed as
described by Di Stefano (21).
For gelatin zymography, conditioned media were collected
from confluent MCF10A.B2 cells treated with AP1510 in
serum-free medium for 18 h and processed as described by
Kim et al. (22). Image J software (U.S. National Institutes of
Health, Bethesda, MD, USA) was used for blot quantification.
In vitro assays
Foci formation was evaluated as described previously (23).
Soft agar colonies were evaluated by seeding in triplicate on
top of 0.4% agar in 6-well plates 104 MEFs/well in DMEM-
10% FCS or 3  104 N202-1A/well in DMEM-20% FCS mixed
1:1 with 0.8% agar (Sigma). To evaluate anoikis, N202.1A
cells were grown in suspension for 24 h on dishes coated with
4% agarose in DMEM (1:1). Two-dimensional migration and
invasion assays were performed as by Di Stefano et al. (21).
In vivo assays
N202-1A cells (105) were injected into the fat pad of FVB-
NeuN mice. The incidence and growth of tumors were
evaluated as described by Di Stefano (21). For the experi-
ments of lung colonization, 105 control, silenced, and recon-
stituted N202-1A cells were injected intravenously in tail veins
of nude mice. Drinking water was supplemented with doxy-
cycline (0.1 mg/ml), protected from light, and changed every
2 or 3 d. After 5 wk, lungs were stained by India ink, and
surface lung nodules were counted.
Control or p130Cas SiStable siRNA (NNUUGAC-
UAAUAGUCUACAUUUA) (Dharmacon; Ordda, Erembo-
degem, Belgium) (10 nM in 25 l PBS) were injected
intranipple (24) in 12 wk-old female Balbc NeuT mice
1/wk for 5 wk. Whole-mount analyses were performed as
described by Cappello et al. (25).
In vitro and in vivo extravasation assays
In vitro, 105 human umbilical vein endothelial cells (HUVECs)
stained with CellTracker blue dyes (Invitrogen) were seeded on
transwells coated with 16,5g/ml FN (Costar, pore size 5m) and
allowed to grow for 72 h. 105 N202-1A cells were plated on top of
HUVEC monolayer and allowed to migrate for 72 h. Transwell
bottom sides were fixed, and images were collected by using Zeiss
microscopy at40. For in vivo extravasation assay, 107 cells stained
with CellTracker red dyes (Invitrogen) were injected into the tail
vein of nude mice and lungs were fixed in PFA 4% after 2 h or 48 h
of challenge. Fixed lungs were visualized under stereo microscope
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(Leica MZ 16F; Leica Microsystems, Wetzlar, Germany) using a 1
lens. Red blood cells were counted after 48 h at 40.
Statistical analysis
Statistical analysis was performed using Student’s t test and
Fisher’s exact test. Results are expressed as means  se.
RESULTS
ErbB2 transformation requires p130Cas
To investigate the relevance of p130Cas in ErbB2
transformation, we transiently transfected NIH3T3 cells
with transforming ErbB2 and two different p130Cas-
silencing vectors and performed a focus formation
assay. p130Cas silencing resulted in 80% reduction of
the protein (Fig. 1A, left panel) and up to 55% reduc-
tion in focus forming units (Fig. 1A, right panel), thus
indicating that ErbB2 transformation in NIH3T3 cells is
strongly dependent on p130Cas expression. Moreover,
p130Cas/ mouse embryo fibroblasts (MEFs) derived
from knockout animals (14), their / wild-type
counterparts, and the / MEFs reconstituted with
the p130Cas full-length (FL) protein were infected
with retroviruses expressing human ErbB2 oncogene
(Fig. 1B, left panel), and soft agar assays were per-
formed. Soft agar colonies were counted within 2 wk
from plating. Notably, wild-type MEFs did not form
colonies in soft agar, and they acquired the ability to
grow in anchorage-independent conditions only fol-
lowing transformation with ErbB2. On the contrary,
ErbB2 infection of p130Cas/ MEFs was not suffi-
cient to drive colony formation. Consistently, reex-
pression of the FL protein in ErbB2 infected
p130Cas/ cells rescued the capacity of forming
colonies in soft agar (Fig. 1B, left panel), indicating
that p130Cas is required for anchorage-independent
growth induced by ErbB2.
p130Cas down-regulation was performed in N202-1A
breast cancer epithelial cells, which are derived from
mammary tumors overexpressing NeuN (17). We gen-
erated cells expressing doxycycline-inducible p130Cas
shRNAs or control scramble shRNA sequences. Within
48 h of doxycycline treatment, p130Cas expression was
effectively silenced of75% compared to cells infected
with scramble sequences, reaching the lowest level at
Figure 1. p130Cas expression is essential for ErbB2
anchorage-independent growth. A) Left panel: total
cell extracts from NIH3T3 transiently cotrans-
fected with activated ErbB2 and shRNA vectors
(pSuper Retro, pLVTHM) expressing the scram-
ble control (Ctr shRNA) or the silencing se-
quence against p130Cas (p130Cas shRNA) were
blotted with p130Cas antibodies. Actin was used as
a loading control. Right panel: focus formation assays were performed with cells transfected as indicated above. As
further control, NIH3T3 cells transfected with ErbB2 alone were used. Average  sd number of foci was calculated
from 3 independent assays performed in triplicates; images of a representative experiment are shown on the right.
B) Left panel: cell extracts derived from pBabe ErbB2-infected Cas/, Cas/, and Cas/ reconstituted with FL
p130Cas-GFP MEFs were blotted with antibodies to ErbB2 (185 kDa, top panel), p130Cas (middle panel), and actin
as loading control (bottom panel). MW markers are shown at left. Note that the FL (p130Cas-GFP) runs at 160 kDa.
Right panel: uninfected Cas/ and Cas/, Cas/ and Cas FL MEFs infected with pBabe-ErbB2 were subjected to
soft agar assays. Statistically significant quantification of visible colonies and representative images taken at 2 wk of
growth are shown. Experiments were repeated 5 times in triplicate. C) Top panel: N202-1A cells were infected with
lentiviruses expressing scramble shRNA (Ctr shRNA) or p130Cas shRNAs (p130Cas shRNA) and treated or not with
doxycycline for 72 h. Total cell extracts were blotted with p130Cas antibodies and actin for loading control. Bottom
panel: same cells were subjected to soft agar assays. Quantification of visible colonies in 3 independent experiments
performed in triplicate and representative images taken at 3 wk of growth are shown. *P  0.01.
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72 h (Fig. 1C, top panel). In soft agar assays, p130Cas-
silenced cells demonstrated a 4-fold decrease in the
number of colonies (Fig. 1C, bottom panel), indicating
that the down-regulation of p130Cas is sufficient to
significantly impair anchorage-independent growth of
tumor cells overexpressing the ErbB2 proto-oncogene.
p130Cas silencing impairs in vivo tumor growth
To investigate the relevance of p130Cas in ErbB2-
dependent tumor growth, N202-1A cells expressing
doxycycline-inducible p130Cas shRNAs, control scram-
ble shRNA sequences, or silenced cells reconstituted by
transiently transfection with human p130Cas full-length
cDNA to recover protein expression (Fig. 2A) were
orthotopically injected into the mammary fat pad of
FVB-NeuN mice. Mice were provided with doxycycline-
supplemented drinking water. p130Cas silenced cells
gave rise to tumors only in 6 of 10 mice, and these
tumors were significantly smaller in size compared to
scramble and reconstituted cells (Fig. 2B).
As an alternative approach, to assess the role of
p130Cas in the growth of ErbB2-dependent spontane-
ous tumors, Balbc NeuT mice (26), which develop focal
mammary tumors at 8 wk of age, were used. Control or
p130Cas-stabilized siRNAs were locally delivered by
intranipple injection (24) in the fourth mammary
gland of 12-wk-old mice, and the treatment was re-
peated weekly for 5 wk. Mice were sacrificed at wk 18.
Whole-mount analysis showed that mammary glands
treated with p130Cas siRNAs developed significantly
less severe lesions than glands injected with control
siRNAs (Fig. 2C). Moreover, Western blot analysis of
mammary gland extracts revealed that p130Cas was
effectively knocked down in vivo by specific siRNA
injection, and its down-regulation correlated with de-
creased Fak phosphorylation, Src and Akt activation,
and reduced level of cyclin D1 (Fig. 2D). Thus, these
experiments demonstrate that selective knockdown of
p130Cas impairs orthotopic ErbB2-dependent tumor
formation. In addition, p130Cas silencing during the
progression of spontaneous ErbB2 tumors is sufficient
to significantly decrease their growth.
In ErbB2-transformed cells, Fak and c-Src signaling is
dependent on p130Cas, and p130Cas is required for
the assembly of a macromolecular complex with
ErbB2, Fak and c-Src
It is known that c-Src and Fak associate to p130Cas and
that c-Src activation accounts for p130Cas and Fak
phosphorylation, creating signaling platforms that reg-
ulate receptor tyrosine kinase activity and downstream
signaling (8). Analysis of cell extracts revealed that the
Figure 2. p130Cas is required for in vivo ErbB2 tumorigenesis. A) Total cell
extracts from infected N202-1A cells expressing scramble shRNA (Ctr shRNA),
p130Cas shRNAs (p130Cas shRNA), and silenced cells reconstituted with the
human full-length p130Cas (p130Cas shRNAhFL Cas) were blotted with
antibodies to p130Cas and actin as loading control. B) Cells as in A were
orthotopically injected into FVB-NeuN mice, and tumor diameter was measured
1/wk within 21 d. Top panel: quantification of number and size of tumors at 21 d after injection. *P 0.05 (Fisher’s exact
test). Bottom panel: mean diameter is reported on the y axis. **P  0.001; ns, P 	 0.2 (Student’s t test). C) Intranipple
injection was performed in BalbC-NeuT female mice. Control (Ctr siRNA) or p130Cas-stabilized siRNA (p130Cas siRNA)
was injected 1/wk for 5 wk starting from wk 12. Top panels: whole-mount analyses of fixed mammary gland at wk 18. The
gland is composed of a tree-like structure of branching ducts. Small lesions that have histological aspects of a solid
carcinoma are visible. Black arrows indicate the lymph node. Ctr siRNA picture shows larger lesions on the right of the
lymph node. Bottom panel: histogram shows the mean tumor volume measured from 2 independent experiments with 8
mice/group. *P  0.0329 (2-tailed P value). D) Protein extracts were prepared from mammary glands from Ctr (no. 1, no.
2) and p130Cas siRNA intranipple-injected mice (no. 3, no. 4). Western blot analysis was performed with antibodies to
p130Cas, pTyr925Fak, p125Fak, pTyr416Src, c-Src, pSer473Akt, Akt, cyclinD1, cytokeratin 18, and vinculin as loading
control.
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phosphorylation of pTyr416 Src and pTyr925 Fak, a
known c-Src substrate, was reduced by 75% in p130Cas
silenced N202-1A cells compared to control and to
human p130Cas reconstituted cells (Fig. 3A). Thus, in
cells transformed by ErbB2, p130Cas controls c-Src
activation and the efficient phosphorylation of Fak.
When control N202-1A cell extracts were immuno-
precipitated with p130Cas antibodies, ErbB2, Fak, and
c-Src were found to coimmunoprecipitate with p130Cas
(Fig. 3B). To assess the specific contribution of p130Cas
in the complex formation, cell extracts of control and
p130Cas-silenced N202-1A cells were immunoprecipi-
tated with antibodies specific for ErbB2, Fak and c-Src
(Fig. 3C). Interestingly, in p130Cas silenced cells recip-
rocal immunoprecipitation experiments showed that
the association of ErbB2 with Fak and c-Src was mark-
edly reduced as well as the complex between Fak and
c-Src (Fig. 3C), indicating that down-regulation of
p130Cas profoundly affects the assembly of the macro-
molecular complex. Tyrosine phosphorylation could be
relevant for the association of the molecules. There-
fore, to assess the contribution of kinase activity in
complex formation, pharmacological inhibitors for c-
Src (SU6656), Fak (PT573228), and ErbB2 (Lapatinib)
were used. The capacity of each inhibitor to inhibit Src
and Fak activation and ErbB2 phosphorylation was
tested (Fig. 3D). The association of ErbB2, p130Cas,
Fak, and c-Src was evaluated on control N202-1A cells
Figure 3. p130Cas is required for Fak and
c-Src signaling and takes part of a macro-
molecular complex in ErbB2-transformed
breast cancer cells. A) Total cell extracts
from N202-1A-infected cells expressing
scramble shRNA (Ctr shRNA), p130Cas
shRNAs (p130Cas shRNA), or silenced
cells reconstituted with the human full-
length p130Cas (p130Cas shRNAhFL)
treated with doxycycline for 72 h were
evaluated by Western blot analysis for
pTyr925Fak, p125Fak, pTyr416Src, c-
Src, and vinculin as loading control.
Results are representative of 3 indepen-
dent experiments. B) Cell extracts from
N202-1A cells expressing scramble
shRNA (Ctr shRNA) in the presence of
doxycycline were immunoprecipitated
with isotype-specific antibodies (PI) or
mAbs for p130Cas. Immunoprecipi-
tates were blotted with antibodies to ErbB2, p130Cas, p125Fak, and cSrc. C) N202-1A cells expressing scramble shRNA
(Ctr shRNA) or p130Cas shRNAs (p130Cas shRNA) in the presence of doxycycline were immunoprecipitated with
mAbs for ErbB2, p125Fak, and c-Src. Top panel: immunoprecipitates and total cell extracts were blotted with
antibodies to ErbB2, p130Cas, p125Fak, c-Src, and actin for loading control. Bottom panel: illustrative graph
visualizing changes in association of the proteins in the different immunoprecipitates. Amount of associated protein
in p130Cas-silenced cells is reported as the percentage of that found in control cells. *Note that in the ErbB2
immunoprecipitates, p130Cas was not detected, probably due to inaccessibility of the epitope. D) Top panel: total cell
extracts from N202-1A cells untreated or treated with 10 M c-Src inhibitor (SU6656), 10 nM p125Fak inhibitor
(PT573228) and with 0.5 M ErbB2 inhibitor (Lapatinib) were immunoprecipitated with ErbB2 antibodies.
Immunoprecipitates were evaluated by Western blot for phosphorylation of ErbB2 (pTyr). Bottom panel: Total cell
extracts were blotted for pTyr397Fak, p125Fak, pTyr416Src, and c-Src. Results are representative of 3 independent
experiments. E) Cell extracts from N202-1A cells untreated or treated as in D were immunoprecipitated with
isotype-specific antibodies (PI) and with mAbs for ErbB2, p130Cas, p125Fak, and c-Src. Immunoprecipitates were
blotted with antibodies to ErbB2, p130Cas, p125Fak, and c-Src. *As in C, in the ErbB2 immunoprecipitates, p130Cas
was not detected, probably due to inaccessibility of the epitope.
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untreated or treated with each of the three inhibitors
by immunoprecipitation with antibodies specific for
ErbB2, p130Cas, Fak, and c-Src and reciprocal Western
blot analysis. In cells treated with Lapatinib, reciprocal
immunoprecipitations show that ErbB2 kinase activity
was required for its immunoprecipitation with c-Src,
and for its association with p130Cas, indicating that the
inhibition of the catalytic activity of ErbB2 impairs its
association with p130Cas and c-Src. The treatment with
the c-Src inhibitor (SU6656) mainly impaired c-Src
association with p130Cas, but it did not affect the
association of ErbB2 and p130Cas. When Fak was
inhibited with PT573228, the relative immunoprecipi-
tation levels did not change, suggesting that the cata-
lytic activity of Fak is not relevant for the assembly of
the macromolecular complex (Fig. 3E). Taken to-
gether, these data indicate that the major components
driving the formation of the complex are p130Cas and
active ErbB2, while active c-Src is required for its
association with p130Cas. A role for Fak as an adaptor
cannot be excluded.
In agreement with the data reported in N202-1A
cells, ErbB2, c-Src, and Fak were found in p130Cas
immunoprecipitates in FL-expressing MEFs, and the
amounts of ErbB2 and Fak were reduced in c-Src
immunoprecipitates in p130Cas/ MEFs (Supplemen-
tal Fig. 1A). Consistently, when cell extracts from
p130Cas/, p130Cas/, and FL-reconstituted MEFs
transformed by ErbB2 were analyzed; phosphorylation
of pTyr925 Fak and pTyr416 Src was higher in
p130Cas/ and FL-reconstituted cells compared to
p130Cas/ MEFs (Supplemental Fig. 1B).
In summary, these data indicate that in ErbB2-
transformed cells, c-Src and Fak signaling are depen-
dent on the presence of p130Cas and that p130Cas is a
key player for the assembly of a ErbB2/c-Src/Fak
molecular complex.
p130Cas is tyrosine phosphorylated on activation of
ErbB2 and increases the extent of downstream
signaling
To study the effects of ErbB2 activation on p130Cas
and downstream signaling, we used the human
10A.B2 cells expressing the ErbB2 chimera, which is
activated by treatment with the synthetic ligand
AP1510 (27). Extracts from 10A.B2 cells treated or
not with AP1510 were immunoprecipitated with
ErbB2 and p130Cas antibodies. As shown in Fig. 4A,
ErbB2 and p130Cas phosphorylation started at 5 min
of stimulation and persisted over time. Interestingly,
c-Src activation was not detectable at 5 min, but it
occurred after 15 min of treatment. Moreover, treat-
ment of cells with the c-Src inhibitor SU6656 did not
prevent p130Cas phosphorylation (data not shown),
indicating that the early p130Cas phosphorylation is
dependent on ErbB2, but not on c-Src activity.
10A.B2 cells were infected with retroviral particles
carrying p130Cas-GFP cDNA (10A.B2Cas) or the
appropriate control (10A.B2mock) and analyzed for
p130Cas levels (Fig. 4B). In addition, tyrosine phos-
phorylation analysis of GFP-p130Cas chimeric prod-
uct and of endogenous p130Cas showed that both
proteins are phosphorylated at comparable levels on
5 min of AP1510 treatment (Supplemental Fig. 2).
Interestingly, in 10A.B2Cas cells in absence of
AP1510, ErbB2 tyrosine phosphorylation was higher
compared to 10A.B2mock cells, suggesting that high
levels of p130Cas function as a priming event for a
partial activation of the receptor (Fig. 4C).
In addition, 10A.B2mock and 10A.B2Cas cells were
treated with AP1510, and cell extracts were analyzed for
activation of c-Src, Akt and Erk1/2 MAPK, and Fak
phosphorylation. p130Cas overexpression in 10A.B2
cells leads to increased activation of c-Src, Erk1/2, Akt,
and to higher Fak phosphorylation over the mock cells,
even in the absence of AP1510 (Fig. 4D). In 10A.B2Cas
cells, p130Cas coimmunoprecipitates with ErbB2, Src,
and Fak (data not shown), suggesting that these mole-
cules associate also in this cellular model.
These data indicate that increased levels of p130Cas
are sufficient to induce tyrosine phosphorylation of
ErbB2 and to strengthen activation of downstream
signaling pathways.
p130Cas overexpression confers invasive properties
to activated ErbB2 in a three-dimensional (3-D)
model of epithelial acini
In 3-D cultures, 10A.B2 cells forms acini-like spheroids
that recapitulate the terminal ductal lobular unit of
human adult breast. Activation of ErbB2 disrupts the
morphogenetic process giving rise to multiacinar, non-
invasive structures, mimicking the early stages of breast
cancer (27).
When plated on a 3-D basement membrane (Matri-
gel/collagen I 1:1), 10A.B2mock cells formed normal
acini (Fig. 5Aa, b), which in the presence of AP1510
ligand, converted into multiacinar structures (Fig. 5Ac,
d). In contrast, 10A.B2Cas cells gave rise to multiacinar
structures (Fig. 5Ae, f) that were positive for the prolif-
erating cell antigen Ki-67 (Supplemental Fig. 3). Fur-
ther, their formation was prevented by treatment with
the ErbB2 inhibitor lapatinib, suggesting that p130Cas-
dependent partial activation of ErbB2 may account for
multiacinar phenotype (Supplemental Fig. 4). These
data indicate that increased levels of p130Cas, in 3-D
cultures, promote proliferation and multiacinar forma-
tion. Interestingly, when 10A.B2Cas cells were treated
with AP1510, 50% of the large multiacinar structures
showed invasive protrusions (Fig. 5Ag, h; arrows),
which, as shown by time-lapse microscopy (Fig. 5B,
bottom panels), originated from the bulk multiacinar
structure. These protrusions were not detectable either
in untreated 10A.B2Cas cells or in mock cells stimu-
lated with AP1510 (Fig. 5B, top panels). To determine
whether invasion was associated with breakdown of the
basement membrane, 3-D acini were stained for lami-
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nin V, a major component of basal membranes. A
continuous layer of laminin V surrounded 10A.B2mock
treated acini (Fig. 5C b). On the contrary, in the
10A.B2Cas treated acini, laminin staining showed
points of breakage corresponding to invading cells
(Fig. 5Cd, De–h; arrows). For studying molecular mech-
anisms related to the invasive phenotype, transwell
invasion assays were performed through a layer of
Matrigel-coated membranes. 10A.B2Cas, in the pres-
ence of ErbB2 activation, invaded 2 times more com-
pared to control cells (Fig. 6A). In the same experimen-
tal set, Rac1 activity measured by pulldown assay was
markedly increased in 10A.B2Cas, compared to mock
cells, on ErbB2 activation (Fig. 6B). Consistently, gela-
tin zymography assays showed that the matrix metallo-
proteinase 9 (MMP9) activity was higher on concomi-
tant activation of ErbB2 and p130Cas overexpression
(Fig. 6C). Taken together, these results clearly indicate
that, while ErbB2 activation does not give rise to
invasion of basement membranes (28), concomitant
activation of ErbB2 and overexpression of p130Cas lead
to the acquirement of invasive properties in human
breast cancer epithelial cells.
p130Cas controls motility, invasion, and lung
colonization of ErbB2-transformed cells
To evaluate whether the down-regulation of p130Cas is
sufficient to affect cell migration and invasion of ErbB2-
transformed cells, the N202-1A cells silenced with
p130Cas-shRNAs were analyzed in migration and inva-
sion assays. p130Cas knockdown in N202-1A cells in-
duced a 2-fold decrease in migration (Fig. 7A), as well
as a significant reduction of invasion (Fig. 7B), com-
pared to cells infected with scramble sequences.
Consistently, in p130Cas / MEFs transformed by
ErbB2, the absence of p130Cas resulted in the inability
to migrate and invade, which was rescued by re-expres-
sion of FL p130Cas (data not shown). Indeed, ErbB2-
transformed p130Cas/ MEFs were characterized by a
round morphology and a cortical actin distribution
(Supplemental Fig. 5A), while the p130Cas/- (B) and
the FL-reconstituted cells (C) became elongated with
organized actin stress fibers. Taken together, these data
indicate that ErbB2, in order to promote migration and
invasion of p130Cas/ MEFs, requires p130Cas to
Figure 4. p130Cas is phosphorylated on ErbB2 activation and regulates the extent of ErbB2 downstream signaling. A) 10A.B2
cells stimulated at different times with 1 M AP1510 were immunoprecipitated with mAbs directed to the cytoplasmic domain
of ErbB2 (top panel) and to p130Cas (middle panel). ErbB2 and p130Cas immunoprecipitates were blotted with antibodies to
phosphotyrosine (pTyr) and reblotted with antibodies to ErbB2 and p130Cas, respectively. Total cell extracts were blotted with
antibodies to pTyr416Src and normalized for total c-Src protein level (bottom panel). B) Total cell extracts of 10A.B2mock and
10A.B2Cas cells were probed with mAbs for p130Cas and for vinculin as a loading control. Arrows indicate the molecular mass
of endogenous p130Cas (130 kDa) and of p130Cas-GFP fusion protein (160 kDa). C) Cell extracts from 10A.B2mock and
10A.B2Cas starved cells were immunoprecipitated with mAbs directed to the cytoplasmic domain of ErbB2, and immunopre-
cipitates were blotted with anti-phosphotyrosine antibodies and reblotted with antibodies against ErbB2. D) Left panels: Western
blot analysis of total cell extracts of 10A.B2mock cells and 10A.B2Cas cells treated for different times with AP1510. Cell extracts
were probed with antibodies to pTyr925Fak, p125Fak, pSer473Akt, Akt, pTyr416Src, c-Src, pErk1/2, and Erk1/2. Right panels:
Quantification analysis and significance of 3 independent experiments. *P  0.05.
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induce proper downstream signaling and actin cy-
toskeleton organization.
To further explore the involvement of p130Cas in
invasion, we challenged p130Cas in in vivo lung metas-
tasis formation. Since breast cancer epithelial N202-1A
allografts do not metastasize (data not shown), an
experimental metastasis assay of lung colonization was
performed. N202-1A cells expressing scramble or si-
lencing sequences without or with reconstitution with
human p130Cas were treated with doxycycline and
injected into the tail vein of nude mice, which were
provided with doxycycline-supplemented drinking wa-
ter. After 5 wk, mice injected with p130Cas-silenced
N202-1A cells showed a 70% reduction in the number
of lung metastases with respect to mice injected with
scramble control cells or with p130Cas reconstituted
cells (Fig. 7C).
To assess whether the impaired lung colonization of
p130Cas-silenced cells was due to increased cell death,
anoikis assays were performed. N202-1A cells silenced
with p130Cas-shRNAs and the appropriate controls
were detached and kept in suspension on 4% agarose-
coated plates for 24 h. Indeed, cleaved Caspase-3 was
present only in the extracts of p130Cas knocked-down
cells, indicating that these cells are more susceptible to
apoptosis induced by cell detachment (Fig. 7D). In
addition, to evaluate whether p130Cas silencing can
induce defects in transmigration through the microvas-
culature, in vitro and in vivo extravasation assays were
performed. N202-1A cells silenced with p130Cas-
shRNAs and the controls were plated on a monolayer of
HUVECs and left to transmigrate. p130Cas-silenced
cells had impaired ability to transmigrate through the
endothelial barrier, with a 40% decrease of migrating
cells (Fig. 7E). In vivo, N202-1A cells expressing scram-
ble, p130Cas shRNA, or reconstituted cells were in-
jected into the tail vein of nude mice, and mice were
sacrificed after 2 or 48 h. At 2 h, the same number of
cells was detected in the microvasculature of lungs with
all the cell lines used (data not shown). At 48 h, when
Figure 5. p130Cas overexpression and
ErbB2 activation induce invasion in 3-D cul-
tures.A) 10A.B2mock (a–d) and 10A.B2Cas
cells (e–h) were grown in Matrigel/collagen
I (1:1) for 12 d and then left unstimulated
(a, b, e, f) or stimulated for 4 d with AP1510
(c, d, g, h) . Images of acinar structures were
taken at d 16. Two representative fields of 3
independent experiments are shown. Ar-
rows indicate invasive protrusions. B) Live
images of d 14 acinar structures formed by
10A.B2mock (top panels) and 10A.B2Cas
cells (bottom panels) unstimulated or stim-
ulated for 48 h with AP1510. Arrows indicate
invasive structures. C) Laminin staining
(red) of d 16 acini unstimulated (a, c) or
stimulated for 4 d with AP1510 (b, d). Only
10A.B2Cas stimulated cells (d) show laminin
breakpoints (arrows). D) Representative
confocal images of laminin stained
10A.B2mock (a, b), and 10A.B2Cas cells
(e, f) stimulated for 4 d with AP1510.
Laminin breakpoints are indicated by ar-
rows (e, f). Phase contrast images are shown (c, d, g, h). Images were taken at20/0.7 IMM with a Leica TCS-SP5 II confocal
microscope and analyzed with LASAF software. Scale bars 	 100 m (C); 50 m (D).
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cells have already extravasated, the number of p130Cas-
silenced cells detected in the lungs was significantly
decreased compared to control or reconstituted cells
(Fig. 7F). Therefore, increased apoptosis and de-
creased extravasation are both implicated in the severe
reduction of metastasis of p130Cas-silenced cells. In
summary, these data strengthen the role of p130Cas as
a major regulator of the invasive properties of ErbB2-
dependent breast cancer cells.
DISCUSSION
In this work, we demonstrate that p130Cas is required
for ErbB2-mediated transformation and anchorage-
independent growth; is phosphorylated on ErbB2 acti-
vation and is an essential transducer in ErbB2 signaling;
and is necessary for driving migration and invasion of
ErbB2-transformed cells. In addition, p130Cas silenc-
ing in breast cancer cells transformed by the ErbB2
proto-oncogene is sufficient to inhibit in vivo tumor
growth and lung colonization.
p130Cas is required for ErbB2-dependent
transformation and tumor growth
p130Cas is a key signaling molecule that conveys signals
from many amplified or mutated oncogenes, such as
ornithine decarboxylase, Ha-Ras, K-Ras, B-Raf, PTEN,
PIK3CA, c-Src, and ALK oncogenes (14, 29, 30) by
undergoing hyperphosphorylation and association with
multiple signaling partners required for transforma-
tion. The data presented here show that the ErbB2
oncogene requires p130Cas as an essential trans-
ducer to drive foci formation and anchorage-
independent growth. Indeed, we show that the reex-
pression of the FL protein is sufficient to promote
growth of colonies in soft agar in p130Cas-null MEFs
on ErbB2 transformation. Interestingly, when these
cells were kept in suspension to mimic the anchor-
age-independent growth, a sustained activation of
Akt was found in FL expressing cells (Supplemental
Fig. 1C), likely accounting for their growth proper-
ties in soft agar. Thus, p130Cas is essential for
triggering anchorage-independent growth on ErbB2
transformation, likely through the activation of sur-
vival mechanisms (7–9).
The relevance of p130Cas in tumor growth is also
strengthened by in vivo studies, showing that p130Cas
silencing is sufficient to inhibit in vivo ErbB2-depen-
dent tumor formation. The growth of orthotopic tu-
mors in FVB-NeuN mice and spontaneous ErbB2 tu-
mors in FVB-NeuT mice was reduced. Interestingly,
intranipple injection of p130Cas stabilized siRNAs in
the mammary glands of mice in which spontaneous
lesions were already present, was sufficient to silence
p130Cas, to inhibit signaling and to reduce tumor
lesions, indicating that p130Cas might be a potential
therapeutic target for novel therapies using RNA inter-
ference. In summary, these different approaches clearly
Figure 6. Cooperation of p130Cas and ErbB2
enhances Rac1 activity and MMP-9 secretion.
A) 10A.B2mock and 10A.B2Cas cells stimu-
lated with 1 M AP1510 were subjected to
transwell invasion assays. After 48 h, cells were
fixed and stained as described in Di Stefano et al. (21). Top panels: representative images of the bottom side of transwells.
Bottom panel: quantification of cells that invaded through the Matrigel from 3 experiments performed in duplicate.
B) 10A.B2mock and 10A.B2Cas cells were serum starved overnight and then untreated or treated with AP1510 for 15 min.
Top panel, top blots: activated Rac1 was pulled down with the CRIB domain of PAK and detected by Western blot with mAb
directed to Rac1. Bottom blots: total amount of Rac1. Bottom panel: quantification of active Rac1 from 3 independent
experiments. C) 10A.B2mock and 10A.B2Cas cells were seeded onto 12-well plates and incubated for 48 h until they reached
confluency. Cells were switched to serum-free medium without or with AP1510 for 18 h, and medium was collected from
each well and loaded onto 8% polyacrylamide gel impregnated with 0.1% gelatin, as described in Materials and Methods.
Top panel: representative zymogram of MMP9 activity (92 kDa). Bottom panel: quantification of MMP9 activity from three
independent experiments. *P  0.05.
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demonstrate that p130Cas is required for transforma-
tion and in vivo tumor growth driven by the ErbB2
oncogene.
p130Cas is phosphorylated on ErbB2 activation and is
an essential transducer in ErbB2 signaling
At a mechanistic level, we demonstrate that p130Cas is
a component of a macromolecular complex, that in-
cludes ErbB2, Fak, and c-Src. Although previous studies
have demonstrated that c-Src tyrosine kinase interacts
specifically with ErbB2 (31, 32) and that Fak and c-Src
are partners of p130Cas (8), these results point out the
existence of a novel signaling platform, which brings
together all these molecules, and in particular, p130Cas
with ErbB2. The knockdown of p130Cas and the use of
pharmacological inhibitors for ErbB2, c-Src, and Fak
show that the association of the 4 molecules requires
the presence of p130Cas, active ErbB2, and active c-Src.
Interestingly, ErbB2 kinase activity is required for the
assembly of the complex, but p130Cas and c-Src are
associated independently of ErbB2 activation. c-Src
kinase activity is also necessary for its association with
p130Cas, but not for the complex between ErbB2 and
p130Cas. These data suggest that the p130Cas scaffold
might independently associate with c-Src and ErbB2
and that the association of the molecules into the
complex with ErbB2 is finely tuned by tyrosine phos-
phorylation. It has recently been shown that c-Src
association with ErbB2 is not dependent on its SH2 or
Figure 7. p130Cas expression is required for in vitro
and in vivo migration and invasion of ErbB2 trans-
formed cells. A) N202-1A cells infected with lentivi-
ruses expressing scramble shRNA (Ctr shRNA) or
p130Cas shRNAs (p130Cas shRNA) treated with
doxycycline were subjected to transwell migration
assays for 12 h in the presence of 20% FBS. N202-1A
cells in lower chambers were counted at40. Graphs
show average values of 3 independent experiments
with statistical significance. *P  0.05. B) N202-1A
cells as in A were subjected to invasion assays on
Matrigel-coated transwells for 72 h in the presence of
20% FBS. N202-1A cells in bottom chambers were
counted at 40. Graphs show averages value of 3 independent experiments with statistical significance. *P  0.05.
C) N202-1A epithelial cells infected with control shRNA (Ctr shRNA), p130Cas shRNA (p130Cas shRNA), or silenced cells
reconstituted with human p130Cas cDNA (p130Cas shRNAhFL Cas) were injected into tail veins of nude mice. Each
experiment was performed with 5 mice/group. After 5 wk of doxycycline treatment, lungs of nude mice were stained with
India ink, harvested, and fixed. Top panels: representative photographs of lungs from the 3 groups of mice. Bottom panel:
quantification of surface lung nodules from 3 independent experiments with statistical significance. **P  0.01. D) Total
cell extracts from Ctr, p130Cas shRNA, or p130Cas reconstituted N202-1A cells grown in suspension for 24 h were probed
with antibodies to cleaved caspase 3 and normalized for actin for loading control. E) Left panels: Ctr and p130Cas shRNA
N202-1A cells expressing GFP (see Materials and Methods) were plated on a previously seeded monolayer of HUVECs on
transwells and allowed to migrate for 72 h in the presence of 20% FBS. Representative images of HUVEC monolayer stained
with a blue fluorescent dye (left images), and of transmigrated cells after 72 h (right images) are shown. Right panel:
quantification of migrated cells through HUVEC monolayer from 3 independent experiments with statistical significance.
*P  0.001. F) Left panels: cells as in C stained with fluorescent CellTracker red dye were injected into the tail vein of nude
mice (5 mice/group). After 48 h, lungs were harvested and fixed in PFA 4%. Representative images are shown. Right panel:
Graph representing the quantification of fluorescent red cells present in the lung from 3 independent experiments with
statistical significance. *P  0.05.
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SH3 domain or on the phosphorylation or kinase
activity of the receptor (32). Since our data show that
p130Cas silencing disrupts c-Src/ErbB2 interaction, the
relevance of p130Cas in the complex formation might
rely on its ability to promote the conformational
changes that have been suggested to mediate c-Src/
ErbB2 association. However, in our experimental
model, the recruitment of the p130Cas/c-Src complex
to ErbB2 requires ErbB2 activity, implying that phos-
photyrosine-dependent interactions are also relevant.
We cannot exclude that other known ErbB2 binding
partners such as the p85 subunit of PI3K (1), also
participate to this complex.
To point out the role of p130Cas in ErbB2 signaling,
we used an inducible ErbB2 chimera expressed in the
human mammary epithelial 10A.B2 cells (20). In these
cells, p130Cas is tyrosine phosphorylated within 5 min
of ErbB2 induction. p130Cas is a known substrate of
c-Src (33). However, on ErbB2 activation, its phosphor-
ylation occurs prior to ErbB2-mediated c-Src activation
and is not reduced by pharmacological c-Src inhibition.
Thus, in ErbB2-transformed cells, the early tyrosine
phosphorylation of p130Cas correlates with ErbB2 ac-
tivation but not with c-Src activity, suggesting that c-Src
is not involved in early p130Cas phosphorylation.
Interestingly, p130Cas silencing dramatically affects
c-Src activation in N202-1A ErbB2-transformed cells.
Consistently, overexpression of p130Cas cooperates
with ErbB2 activation, leading to a further increase in
c-Src induction and in Fak phosphorylation on the
tyrosine 925, a known phosphorylation site for c-Src,
indicating a role for p130Cas in promoting a positive
loop leading to c-Src induction mediated by ErbB2. In
addition to c-Src, Akt and Erk1/2 MAPK also activities
are up-regulated by high levels of p130Cas. Therefore,
p130Cas per se is a positive regulator of signaling, that
associates and cooperates with active ErbB2, driving
c-Src, Fak, Akt, and Erk1/2 MAPK activation (Fig. 8).
ErbB2 activation in 10A.B2 cells gives rise to multi-
acinar structures (27), reflecting the in vivo amplifica-
tion and activation of ErbB receptors in breast epithe-
lial cells at the onset of malignancy. Our data show that
increased expression of p130Cas in the 10A.B2Cas cells
is sufficient to generate multiacinar structures, likely
through the enhanced basal activity of c-Src, Fak, and
Erk1/2. These multiacini are positive for Ki-67 staining,
indicating that p130Cas overexpression mediates re-
entry into the cell cycle, likely through activation of the
signaling pathways reported above. Consistently, in our
MMTV-p130Cas transgenic mice, overexpression of
p130Cas induces mammary epithelial cell hyperplasia,
characterized by increased activation of proliferation
pathways (10).
p130Cas is required for ErbB2-dependent migration,
invasion and in vivo lung metastasis colonization
ErbB2 activation in 10A.B2 cells does not drive invasion
(27). In contrast when ErbB2 is switched on in the
10A.B2Cas cells, the proliferation program is shut off,
as shown by reduced KI67 staining, and these growth-
arrested multiacinar structures show extensive protru-
sions. These multiacinar structures switch from a sta-
tionary to an invasive phenotype, as demonstrated by
discontinuities in the laminin V staining corresponding
to invading cells. Moreover, both Rac1 and MMP9
activities are markedly enhanced, indicating that the
concomitant expression of p130Cas and active ErbB2 is
important for activation of pathways leading to progres-
sion of ErbB2 epithelial transformed cells to an invasive
phenotype.
p130Cas silencing is sufficient to inhibit migration
and invasion in cells transformed by ErbB2. The im-
paired organization of actin stress fibers in ErbB2
transformed p130Cas-null MEFs could account for the
Figure 8. Model for the role of p130Cas in
ErbB2 transformation and invasion. I) In breast
cancer cells, high levels of p130Cas and con-
comitant ErbB2 activation result in enhanced
phosphorylation of p130Cas and activation of
c-Src, Fak, and Akt, leading to transformation
and invasion. II) Conversely, low levels of
p130Cas prevent the activation of downstream
signaling, resulting in impaired tumorigenic
properties.
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observed defects in the migratory/invasive machinery.
p130Cas is involved in cell migration and invasion,
mainly through its tyrosine phosphorylation by c-Src,
and the assembly of a p130Cas/Crk/DOCK180 scaffold
at lamellipodia and filopodia adhesion sites (34, 35),
which ultimately leads to JNK activation and matrix
metalloproteinases induction (36–38). In addition, in
Fak-null MEFs, which are inhibited in migratory and
invasive properties, even in the presence of oncogenic
v-Src (39), the expression of p130Cas is sufficient to
rescue invasion defects. Moreover, p130Cas has also
been shown to enhance the capacity of oncogenic Src
to invade through basement membranes in MEF-trans-
formed fibroblasts (40). In mammary adenocarcinoma
cell lines, ErbB2-dependent invasion has also been
found to correlate with the coupling of p130Cas to Crk
(41). Therefore, our data highlight the presence of a
signaling platform, including ErbB2, Fak, c-Src, and
p130Cas, where p130Cas is essential for driving migra-
tion and invasion.
Finally, p130Cas silencing efficiently prevents the
lung metastasis colonization of ErbB2-transformed
cells, by both increasing their susceptibility to apoptosis
and impairing their ability to transmigrate through the
endothelial barrier. This observation places p130Cas as
a new player in the extravasation process, likely through
its capacity to influence actin cytoskeleton remodeling.
In summary, this work outlines the essential role of
p130Cas in ErbB2 tumor formation and in the acquire-
ment of metastatic properties, providing evidences that
p130Cas silencing might be a useful translational tool
to prevent breast primary tumors to grow, to invade and
to metastasize.
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